Answers are grounded in this paper and cite their sources.
A rare case demonstrates profound hypocalcemia in a 64-year-old woman with extensive cranial involvement, indicating unique clinical implications.
Introduction Paget's disease of bone is a metabolic bone disorder characterized by abnormal bone remodeling and is often detected incidentally through elevated alkaline phosphatase (ALP) or pathological fractures. Presentation with severe hypocalcemia is unusual. Here, we describe a rare case of Paget's disease admitted to the emergency department with profound hypocalcemia and extensive cranial bone involvement. Clinical Case A 64-year-old woman presented with progressive somnolence and speech difficulties. Neurological evaluation revealed disorientation with a Glasgow Coma Scale score of 11, frontal and temporal bone prominence, and increased head size. Cranial changes had gradually progressed over the previous four years, with hearing loss and recurrent headaches emerging during the last two years. Her vital signs were stable. Chvostek’s and Trousseau’s signs were positive. Arterial blood gas analysis revealed pH 7.39, bicarbonate (HCO₃⁻) 30 mmol/L, and ionized calcium 2.3 mg/dL. Brain CT and diffusion MRI excluded acute stroke and intracranial hemorrhage. ECG demonstrated a prolonged QT interval of 490 ms. Laboratory tests showed severe hypocalcemia (Ca: 4.1 mg/dL), low phosphorus (2.1 mg/dL), markedly elevated ALP (1550 U/L), low vitamin D (<5 ng/mL), elevated parathyroid hormone (PTH: 125 pg/mL), and reduced 24-hour urinary calcium excretion (32 mg/day). She was treated with intravenous calcium infusion together with magnesium, requiring 8–10 ampoules of calcium gluconate daily (≈0.74–0.93 g elemental calcium) to maintain normocalcemia. She also received 150,000 IU/week intramuscular cholecalciferol, and oral calcitriol was initiated at 0.5 mcg/day. Electrolytes and clinical status were monitored daily. Skull X-ray revealed mixed lytic and sclerotic lesions consistent with the classic “cotton wool” appearance. Bone scintigraphy showed diffuse cranial uptake, suggesting active-phase Paget’s disease. The maximal skull thickness measured 6 cm. Given the extensive cranial involvement and unusual biochemical presentation, clinical exome sequencing was performed, which did not reveal any germline variant to explain this presentation. By the 10th day of hospitalization, her oral intake had improved, and intravenous treatment was tapered. She was discharged after stabilization with a prescription including 40,000 IU/week of cholecalciferol, 3 g/day of oral calcium carbonate, and 365 mg/day of oral magnesium supplementation. At her 3-month follow-up, laboratory results were: PTH 40.7 pg/mL, creatinine 0.9 mg/dL, calcium 9.7 mg/dL, phosphorus 3.8 mg/dL, albumin 4.0 g/dL, magnesium 2.0 mg/dL, and ALP 1000 U/L. She received 5 mg intravenous zoledronic acid at that visit. Conclusion This case illustrates a rare presentation of Paget’s disease with severe hypocalcemia and massive skull involvement. Although radiological findings were consistent with Paget’s disease of bone, other causes of cranial bone thickening, such as osteopetrosis, should be excluded.Figure 1:Lateral skull X-ray of a patient with Paget’s disease of bone, showing massive cranial involvement with mixed lytic and sclerotic changes, giving the classic “cotton wool” appearance. Table 1:Laboratory Findings and Treatment Timeline in Paget’s DiseaseLaboratory parameters at admission and after treatment in a patient with Paget’s disease presenting with profound hypocalcemia and massive skull involvement. The table also summarizes the therapeutic interventions administered during hospitalization and follow-up.
No takes yet. Share an insight, caveat, or question.
Solak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: